Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Serial ctDNA monitoring during adjuvant capecitabine in early triple-negative breast cancer

Phase 2 trial of adjuvant capecitabine with serial ctDNA monitoring. The registry primary outcome is the baseline level of ctDNA detection. ClinicalTrials.gov lists the study as recruiting.

Stanford University